The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up of the global ARCHES study led by the Duke Cancer Institute.
This article was originally published on MedicalXpress.com
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
© 2025 SimplyWell.ca